Morgan Stanley raised the firm’s price target on Shoulder Innovations (SI) to $23 from $18 and keeps an Overweight rating on the shares. Going into 2026, MedTech “looks well-positioned on several fronts” as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for “a solid industry setup,” the analyst tells investors in a note for the group on the upcoming year.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SI:
- Promising Outlook for Shoulder Innovations, Inc.: Buy Rating Affirmed by Patrick Wood
- Shoulder Innovations Reports Strong Q3 Growth and Raises Guidance
- Closing Bell Movers: AMD up 5% after unveiling medium term targets
- Shoulder Innovations reports Q3 EPS (64c), consensus (37c)
- Shoulder Innovations raises FY25 revenue view to $45M-$46M from $42M-$44M